Loading...

Morgan, Timothy R

TitleProfessor In Residence
InstitutionUniversity of California, Irvine
DepartmentMedicine
Address1001 Health Sciences Road
CA 92697-3950
Phone(562) 826-5756
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Belperio PS, Chartier M, Gonzalez RI, Park AM, Ross DB, Morgan T, Backus LI. Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success. Infect Dis Clin North Am. 2018 Jun; 32(2):281-292. PMID: 29778256.
      View in: PubMed
    2. Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson S, Sidhu SS, O'Grady JG, Akriviadis E, Sinakos E, Carithers RL, Ramond MJ, Maddrey WC, Morgan T, Duhamel A, Mathurin P. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data. Gastroenterology. 2018 May 05. PMID: 29738698.
      View in: PubMed
    3. Morgan T. Extracorporeal liver assist device for alcoholic hepatitis: A potential silver lining? Liver Transpl. 2018 03; 24(3):330-332. PMID: 29365343.
      View in: PubMed
    4. Khanova E, Wu R, Wang W, Yan R, Chen Y, French SW, Llorente C, Pan SQ, Yang Q, Li Y, Lazaro R, Ansong C, Smith RD, Bataller R, Morgan T, Schnabl B, Tsukamoto H. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. Hepatology. 2018 May; 67(5):1737-1753. PMID: 29108122.
      View in: PubMed
    5. Lu JG, Nguyen L, Samadzadeh S, Masouminia M, Mendoza A, Sweeney O, Tillman B, Afifyan N, Morgan T, French BA, French SW. Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins. Exp Mol Pathol. 2018 Apr; 104(2):125-129. PMID: 29425759.
      View in: PubMed
    6. Nguyen L, Masouminia M, Mendoza A, Samadzadeh S, Tillman B, Morgan T, French B, French S. Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis. Exp Mol Pathol. 2018 Feb; 104(1):45-49. PMID: 29307797.
      View in: PubMed
    7. Morgan T. Treatment of Alcoholic Liver Disease. Gastroenterol Hepatol (N Y). 2017 Jul; 13(7):425-427. PMID: 28867971.
      View in: PubMed
    8. Wade EM, Jenkins ZA, Daniel PB, Morgan T, Addor MC, Adés LC, Bertola D, Bohring A, Carter E, Cho TJ, de Geus CM, Duba HC, Fletcher E, Hadzsiev K, Hennekam RCM, Kim CA, Krakow D, Morava E, Neuhann T, Sillence D, Superti-Furga A, Veenstra-Knol HE, Wieczorek D, Wilson LC, Markie DM, Robertson SP. Autosomal dominant frontometaphyseal dysplasia: Delineation of the clinical phenotype. Am J Med Genet A. 2017 May 12. PMID: 28498505.
      View in: PubMed
    9. Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Kirchner JE, Proctor EK, Gonzalez R, Park A, Ross D, Morgan T, Chartier M, Chinman MJ. The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. Implement Sci. 2017 05 11; 12(1):60. PMID: 28494811.
      View in: PubMed
    10. O'Brien TR, Kottilil S, Feld JJ, Morgan T, Pfeiffer RM. Race or genetic makeup for hepatitis C virus treatment decisions? Hepatology. 2017 06; 65(6):2124-2125. PMID: 28100007.
      View in: PubMed
    11. Loftfield E, O'Brien TR, Pfeiffer RM, Howell CD, Horst R, Prokunina-Olsson L, Weinstein SJ, Albanes D, Morgan T, Freedman ND. Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. PLoS One. 2016; 11(11):e0166036. PMID: 27832143.
      View in: PubMed
    12. Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan T, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845. PMID: 27740516.
      View in: PubMed
    13. Wade EM, Daniel PB, Jenkins ZA, McInerney-Leo A, Leo P, Morgan T, Addor MC, Adès LC, Bertola D, Bohring A, Carter E, Cho TJ, Duba HC, Fletcher E, Kim CA, Krakow D, Morava E, Neuhann T, Superti-Furga A, Veenstra-Knol I, Wieczorek D, Wilson LC, Hennekam RC, Sutherland-Smith AJ, Strom TM, Wilkie AO, Brown MA, Duncan EL, Markie DM, Robertson SP. Mutations in MAP3K7 that Alter the Activity of the TAK1 Signaling Complex Cause Frontometaphyseal Dysplasia. Am J Hum Genet. 2016 Aug 04; 99(2):392-406. PMID: 27426733; PMCID: PMC4974064 [Available on 02/04/17].
    14. Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, Dvory-Sobol H, Zhu Y, Brainard DM, Guyer W, Shaikh O, Fuchs M, Morgan T. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. Clin Gastroenterol Hepatol. 2017 02; 15(2):282-288. PMID: 27237429.
      View in: PubMed
    15. Cozen ML, Ryan JC, Shen H, Cheung R, Kaplan DE, Pocha C, Brau N, Aytaman A, Schmidt WN, Pedrosa M, Anand BS, Chang KM, Morgan T, Monto A. Improved Survival Among all Interferon-a-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Dig Dis Sci. 2016 06; 61(6):1744-56. PMID: 27059981.
      View in: PubMed
    16. Thursz M, Morgan T. Treatment of Severe Alcoholic Hepatitis. Gastroenterology. 2016 Jun; 150(8):1823-34. PMID: 26948886.
      View in: PubMed
    17. Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC, Morgan T, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology. 2016 Apr; 150(4):785-90. PMID: 26921783.
      View in: PubMed
    18. Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, Eggebeen J, Nicklas BJ. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016 Jan 05; 315(1):36-46. PMID: 26746456; PMCID: PMC4787295 [Available on 01/05/17].
    19. Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 01; 163(11):818-26. PMID: 26551051.
      View in: PubMed
    20. LaFleur J, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Han J, Knippenberg K, Nelson RE. Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C. Gastroenterol Nurs. 2015 Nov-Dec; 38(6):417-28. PMID: 26626031.
      View in: PubMed
    21. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan T, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):714-25. PMID: 26196502.
      View in: PubMed
    22. O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan T, Strickler HD, Thomas DL, Prokunina-Olsson L. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015 Nov; 63(5):1103-10. PMID: 26186989.
      View in: PubMed
    23. Morgan T, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu KQ, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL. A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum a-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prev Res (Phila). 2015 Sep; 8(9):864-72. PMID: 26130251; PMCID: PMC4560676.
    24. Whitfield JB, Rahman K, Haber PS, Day CP, Masson S, Daly AK, Cordell HJ, Mueller S, Seitz HK, Liangpunsakul S, Westerhold C, Liang T, Lumeng L, Foroud T, Nalpas B, Mathurin P, Stickel F, Soyka M, Botwin GJ, Morgan T, Seth D. Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study. Alcohol Clin Exp Res. 2015 May; 39(5):836-42. PMID: 25872595; PMCID: PMC4398999.
    25. Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O'Grady J, Trépo E, Nahon P, Ganne-Carrié N, Naveau S, Diaz E, Gustot T, Lassailly G, Cannesson-Leroy A, Canva-Delcambre V, Dharancy S, Park SH, Moreno C, Morgan T, Duhamel A, Mathurin P. Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis. Gastroenterology. 2015 Aug; 149(2):398-406.e8; quiz e16-7. PMID: 25935634.
      View in: PubMed
    26. Gillen DL, Meyskens FL, Morgan T, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM. A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prev Res (Phila). 2015 Mar; 8(3):222-30. PMID: 25604134; PMCID: PMC4355051.
    27. Nguyen DL, Chao D, Ma G, Morgan T. Quality of life and factors predictive of burden among primary caregivers of chronic liver disease patients. Ann Gastroenterol. 2015 Jan-Mar; 28(1):124-129. PMID: 25608915.
      View in: PubMed
    28. Morgan T. Corticosteroids can be used to treat alcoholic hepatitis after a recent upper gastrointestinal bleed. J Hepatol. 2015 Apr; 62(4):759-60. PMID: 25543081.
      View in: PubMed
    29. Yun JW, Son MJ, Abdelmegeed MA, Banerjee A, Morgan T, Yoo SH, Song BJ. Binge alcohol promotes hypoxic liver injury through a CYP2E1-HIF-1a-dependent apoptosis pathway in mice and humans. Free Radic Biol Med. 2014 Dec; 77:183-94. PMID: 25236742.
      View in: PubMed
    30. Nguyen DL, Morgan T. Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view. Hepatol Int. 2014 Sep 01; 8(2):447-51. PMID: 25525477; PMCID: PMC4267851.
    31. Peng Y, French BA, Tillman B, Morgan T, French SW. The inflammasome in alcoholic hepatitis: Its relationship with Mallory-Denk body formation. Exp Mol Pathol. 2014 Oct; 97(2):305-13. PMID: 25149528; PMCID: PMC4177273.
    32. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol. 2014 Oct 15; 114(8):1217-22. PMID: 25159234.
      View in: PubMed
    33. Liu H, Li J, Tillman B, Morgan T, French BA, French SW. TLR3/4 signaling is mediated via the NF?B-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies. Exp Mol Pathol. 2014 Oct; 97(2):234-40. PMID: 24997224; PMCID: PMC4177360.
    34. Chao D, Botwin GJ, Morgan T. Update on recently approved treatments for hepatitis C. Curr Treat Options Gastroenterol. 2014 Jun; 12(2):211-28. PMID: 24648040.
      View in: PubMed
    35. LaFleur J, Hoop R, Morgan T, DuVall SL, Pandya P, Korner E, Knippenberg K, Hayden C, Nelson RE. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res Notes. 2014 Apr 24; 7:266. PMID: 24758162; PMCID: PMC4012175.
    36. Nelson RE, Hoop R, Korner E, DuVall S, Hayden CL, Knippenberg K, Morgan T, Pandya P, Han J, LaFleur J. Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy. Ann Pharmacother. 2014 Jul; 48(7):826-836. PMID: 24760408.
      View in: PubMed
    37. Botwin GJ, Morgan T. Bacterial infections in cirrhosis. Hepatol Int. 2014 Sep; 8 Suppl 2:467-74. PMID: 26201326.
      View in: PubMed
    38. Wang AS, Pfeiffer RM, Morgan T, O'Brien TR. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology. 2014 Jun; 59(6):2423-4. PMID: 24122888.
      View in: PubMed
    39. Hanley DF, Chabot R, Mould WA, Morgan T, Naunheim R, Sheth KN, Chiang W, Prichep LS. Use of brain electrical activity for the identification of hematomas in mild traumatic brain injury. J Neurotrauma. 2013 Dec 15; 30(24):2051-6. PMID: 24040943.
      View in: PubMed
    40. Cappello S, Gray MJ, Badouel C, Lange S, Einsiedler M, Srour M, Chitayat D, Hamdan FF, Jenkins ZA, Morgan T, Preitner N, Uster T, Thomas J, Shannon P, Morrison V, Di Donato N, Van Maldergem L, Neuhann T, Newbury-Ecob R, Swinkells M, Terhal P, Wilson LC, Zwijnenburg PJ, Sutherland-Smith AJ, Black MA, Markie D, Michaud JL, Simpson MA, Mansour S, McNeill H, Götz M, Robertson SP. Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. Nat Genet. 2013 Nov; 45(11):1300-8. PMID: 24056717.
      View in: PubMed
    41. Kathirvel E, Morgan K, French SW, Morgan T. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease. Nutr Res. 2013 Nov; 33(11):932-41. PMID: 24176233.
      View in: PubMed
    42. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan T, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology. 2013 Nov; 145(5):1035-1044.e5. PMID: 23924660.
      View in: PubMed
    43. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan T, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013 Feb; 45(2):164-71. PMID: 23291588; PMCID: PMC3793390.
    44. Loftis JM, Patterson AL, Wilhelm CJ, McNett H, Morasco BJ, Huckans M, Morgan T, Saperstein S, Asghar A, Hauser P. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. J Psychosom Res. 2013 Jan; 74(1):57-63. PMID: 23272989; PMCID: PMC4408920.
    45. Reinstein E, Frentz S, Morgan T, García-Miñaúr S, Leventer RJ, McGillivray G, Pariani M, van der Steen A, Pope M, Holder-Espinasse M, Scott R, Thompson EM, Robertson T, Coppin B, Siegel R, Bret Zurita M, Rodríguez JI, Morales C, Rodrigues Y, Arcas J, Saggar A, Horton M, Zackai E, Graham JM, Rimoin DL, Robertson SP. Vascular and connective tissue anomalies associated with X-linked periventricular heterotopia due to mutations in Filamin A. Eur J Hum Genet. 2013 May; 21(5):494-502. PMID: 23032111; PMCID: PMC3641385.
    46. French SW, Lee J, Zhong J, Morgan T, Buslon V, Lungo W, French BA. Alcoholic liver disease - Hepatocellular carcinoma transformation. J Gastrointest Oncol. 2012 Sep; 3(3):174-81. PMID: 22943009; PMCID: PMC3418528.
    47. Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan T, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Sep; 107(9):1388-98. PMID: 22688849.
      View in: PubMed
    48. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan T, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012 Sep; 143(3):608-618.e5. PMID: 22626609.
      View in: PubMed
    49. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan T, Monto A. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012 May; 107(5):669-89; quiz 690. PMID: 22525303.
      View in: PubMed
    50. McFarland M, Davis K, Wallace J, Wan J, Cassidy R, Morgan T, Venugopal D. Use of home telehealth monitoring with active medication therapy management by clinical pharmacists in veterans with poorly controlled type 2 diabetes mellitus. Pharmacotherapy. 2012 May; 32(5):420-6. PMID: 22488512.
      View in: PubMed
    51. Nguyen DL, Morgan T. Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection. Clin Liver Dis (Hoboken). 2012 Apr; 1(2):54-57. PMID: 25688295.
      View in: PubMed
    52. Everson GT, Shiffman ML, Hoefs JC, Morgan T, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology. 2012 Apr; 55(4):1019-29. PMID: 22030902; PMCID: PMC3298578.
    53. Sterling RK, Wright EC, Morgan T, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012 Jan; 107(1):64-74. PMID: 21931376.
      View in: PubMed
    54. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan T. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug; 54(2):434-42. PMID: 21374690; PMCID: PMC3134544.
    55. O'Brien TR, Everhart JE, Morgan T, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011; 6(7):e20904. PMID: 21760886.
      View in: PubMed
    56. Dienstag JL, Ghany MG, Morgan T, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405. PMID: 21520194.
      View in: PubMed
    57. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan T, Ghany MG. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8. PMID: 21480316.
      View in: PubMed
    58. Hoefs JC, Morgan T, Ilagan BJ. Testing beneficial therapy in human cirrhosis using animal models of cirrhosis. Dig Dis Sci. 2011 Apr; 56(4):929-30. PMID: 21365242; PMCID: PMC3059786.
    59. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan T, Bonkovsky HL. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May; 140(5):1490-500.e3. PMID: 21335007; PMCID: PMC3081953.
    60. Morgan T. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res. 2011; 188:85-99. PMID: 21253791.
      View in: PubMed
    61. Morgan T, O'Brien TR. IL28B-genotype testing now and in the era of direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2011 Apr; 9(4):293-4. PMID: 21185399; PMCID: PMC3065520.
    62. Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan T, Litman HJ, Reid AE, Lee WM, Naishadham D. Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol. 2011 May; 106(5):884-93. PMID: 21139575.
      View in: PubMed
    63. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan T. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar; 140(3):840-9; quiz e12. PMID: 21129375; PMCID: PMC3057272.
    64. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, Ramond MJ, Naveau S, Maddrey WC, Morgan T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb; 60(2):255-60. PMID: 20940288.
      View in: PubMed
    65. Morgan T, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3):833-44. PMID: 20564351.
      View in: PubMed
    66. Kathirvel E, Morgan K, Nandgiri G, Sandoval BC, Caudill MA, Bottiglieri T, French SW, Morgan T. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol. 2010 Nov; 299(5):G1068-77. PMID: 20724529; PMCID: PMC2993168.
    67. Kathirvel E, Chen P, Morgan K, French SW, Morgan T. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol. 2010 Jun; 25(6):1136-43. PMID: 20594230.
      View in: PubMed
    68. Seeff LB, Everson GT, Morgan T, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010 Oct; 8(10):877-83. PMID: 20362695.
      View in: PubMed
    69. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan T, Everhart JE. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology. 2010 Jun; 138(7):2321-31, 2331.e1-2. PMID: 20211180.
      View in: PubMed
    70. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan T, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009 Dec; 50(6):1738-49. PMID: 19824074.
      View in: PubMed
    71. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan T, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb; 138(2):493-502. PMID: 19852963.
      View in: PubMed
    72. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan T, Dienstag JL. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2010 Jan; 138(1):136-46. PMID: 19766643.
      View in: PubMed
    73. Kathirvel E, Morgan K, French SW, Morgan T. Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009 Sep; 21(9):973-83. PMID: 19307976.
      View in: PubMed
    74. Lucey MR, Mathurin P, Morgan T. Alcoholic hepatitis. N Engl J Med. 2009 Jun 25; 360(26):2758-69. PMID: 19553649.
      View in: PubMed
    75. Ge L, Zhang JG, Samathanam CA, Delgado C, Tarbiyat-Boldaji M, Dan Q, Hoa N, Nguyen TV, Alipanah R, Pham JT, Sanchez R, Wepsic HT, Morgan T, Jadus MR. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor. Cell Immunol. 2009; 259(2):117-27. PMID: 19615673.
      View in: PubMed
    76. Welzel TM, Morgan T, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun; 49(6):1847-58. PMID: 19434718.
      View in: PubMed
    77. Everhart JE, Lok AS, Kim HY, Morgan T, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009 Aug; 137(2):549-57. PMID: 19445938.
      View in: PubMed
    78. Morgan T, Denholm MJ, Lawton S. Re: Palliative sedation at home. J Palliat Care. 2009; 25(3):229; author reply 229. PMID: 19824286.
      View in: PubMed
    79. Butura A, Nilsson K, Morgan K, Morgan T, French SW, Johansson I, Schuppe-Koistinen I, Ingelman-Sundberg M. The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol. 2009 Mar; 50(3):572-83. PMID: 19157621.
      View in: PubMed
    80. Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Miñaur S, Bohring A, Lacombe D, Stewart F, Fiskerstrand T, Bindoff L, Berland S, Adès LC, Tchan M, David A, Wilson LC, Hennekam RC, Donnai D, Mansour S, Cormier-Daire V, Robertson SP. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009 Jan; 41(1):95-100. PMID: 19079258.
      View in: PubMed
    81. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan T, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 04; 359(23):2429-41. PMID: 19052125.
      View in: PubMed
    82. Morishima C, Morgan T, Everhart JE, Wright EC, Apodaca MC, Gretch DR, Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany MG, Curto TM. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology. 2008 Nov; 48(5):1412-9. PMID: 18816437.
      View in: PubMed
    83. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan T, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008 Oct; 48(4):1033-43. PMID: 18697207.
      View in: PubMed
    84. Lok AS, Seeff LB, Morgan T, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan; 136(1):138-48. PMID: 18848939.
      View in: PubMed
    85. Morgan K, Uyuni A, Nandgiri G, Mao L, Castaneda L, Kathirvel E, French SW, Morgan T. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2008 Sep; 20(9):843-54. PMID: 18794597.
      View in: PubMed
    86. Cheung RC, Currie S, Shen H, Bini EJ, Ho SB, Anand BS, Hu KQ, Wright TL, Morgan T. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol. 2008 Aug; 42(7):827-34. PMID: 18285716.
      View in: PubMed
    87. Morgan T, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O'Brien TR. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol. 2008 Oct; 49(4):548-56. PMID: 18619701.
      View in: PubMed
    88. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan T, Ghany MG. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):234-41. PMID: 18237873.
      View in: PubMed
    89. Hoefs JC, Morgan T. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response? Hepatology. 2007 Dec; 46(6):1671-4. PMID: 18046713.
      View in: PubMed
    90. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan T, Ghany MG, Morishima C. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):245-54. PMID: 17296533.
      View in: PubMed
    91. Morgan T. Management of alcoholic hepatitis. Gastroenterol Hepatol (N Y). 2007 Feb; 3(2):97-9. PMID: 21960817; PMCID: PMC3099359.
    92. Hu KQ, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, McCracken JD, Morgan T, Bräu N, Schmidt WN, Jeffers L, Wright TL. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci. 2007 Feb; 52(2):570-8. PMID: 17226072.
      View in: PubMed
    93. Reddy KR, Shiffman ML, Morgan T, Zeuzem S, Hadziyannis S, Hamzeh FM, Wright TL, Fried M. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):124-9. PMID: 17196435.
      View in: PubMed
    94. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan T, Dienstag JL, Ghany MG, Gretch DR. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007 Mar; 46(3):420-31. PMID: 17196293; PMCID: PMC1995129.
    95. Shiffman ML, Ghany MG, Morgan T, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007 Jan; 132(1):103-12. PMID: 17241864.
      View in: PubMed
    96. Morishima C, Morgan T, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology. 2006 Aug; 44(2):360-7. PMID: 16871570.
      View in: PubMed
    97. Lieber CS, Weiss DG, Morgan T, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol. 2006 Jul; 101(7):1500-8. PMID: 16863553.
      View in: PubMed
    98. Jensen DM, Morgan T, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006 May; 43(5):954-60. PMID: 16628671.
      View in: PubMed
    99. Chen SL, Morgan T. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3(2):47-52. PMID: 16614742; PMCID: PMC1415841.
    100. Morgan T. How useful and accurate is the new Glasgow alcoholic hepatitis scoring system? Nat Clin Pract Gastroenterol Hepatol. 2006 Jan; 3(1):14-5. PMID: 16397604.
      View in: PubMed
    101. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan T, Ghany MG, Gretch DR. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005 Sep; 43(3):434-41. PMID: 16136646.
      View in: PubMed
    102. Bini EJ, Bräu N, Currie S, Shen H, Anand BS, Hu KQ, Jeffers L, Ho SB, Johnson D, Schmidt WN, King P, Cheung R, Morgan T, Awad J, Pedrosa M, Chang KM, Aytaman A, Simon F, Hagedorn C, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki AW, Rossi S, Wright TL. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005 Aug; 100(8):1772-9. PMID: 16086714.
      View in: PubMed
    103. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan T, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005 Aug; 42(2):282-92. PMID: 15986415.
      View in: PubMed
    104. Morgan T, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, Kidao J, Cecil B, Mendenhall CL, Nelson D, Lieber C, Pedrosa M, Jeffers L, Bloor J, Lumeng L, Marsano L, McClain C, Mishra G, Myers B, Leo M, Ponomarenko Y, Taylor D, Chedid A, French S, Kanel G, Murray N, Pinto P, Fong TL, Sather MR. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology. 2005 Apr; 128(4):882-90. PMID: 15825072.
      View in: PubMed
    105. Bardag-Gorce F, Wilson L, Nan L, Li J, French BA, Morgan T, Morgan K, French SW. CYP2E1 inhibition enhances mallory body formation. Exp Mol Pathol. 2005 Jun; 78(3):207-11. PMID: 15924872.
      View in: PubMed
    106. Jamal MM, Saadi Z, Morgan T. Alcohol and hepatitis C. Dig Dis. 2005; 23(3-4):285-96. PMID: 16508293.
      View in: PubMed
    107. Morgan T, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004 Nov; 127(5 Suppl 1):S87-96. PMID: 15508108.
      View in: PubMed
    108. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan T, Ghany MG, Morishima C, Wright EC, Everhart JE. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004 Oct; 25(5):472-92. PMID: 15465617.
      View in: PubMed
    109. Cefalu WT, Wang ZQ, Bell-Farrow AD, Collins J, Morgan T, Wagner JD. Caloric restriction and cardiovascular aging in cynomolgus monkeys (Macaca fascicularis): metabolic, physiologic, and atherosclerotic measures from a 4-year intervention trial. J Gerontol A Biol Sci Med Sci. 2004 Oct; 59(10):1007-14. PMID: 15528768.
      View in: PubMed
    110. Mandayam S, Jamal MM, Morgan T. Epidemiology of alcoholic liver disease. Semin Liver Dis. 2004 Aug; 24(3):217-32. PMID: 15349801.
      View in: PubMed
    111. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan T, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr; 126(4):1015-23; discussion 947. PMID: 15057741.
      View in: PubMed
    112. Hadziyannis SJ, Sette H, Morgan T, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 02; 140(5):346-55. PMID: 14996676.
      View in: PubMed
    113. Krakow D, Robertson SP, King LM, Morgan T, Sebald ET, Bertolotto C, Wachsmann-Hogiu S, Acuna D, Shapiro SS, Takafuta T, Aftimos S, Kim CA, Firth H, Steiner CE, Cormier-Daire V, Superti-Furga A, Bonafe L, Graham JM, Grix A, Bacino CA, Allanson J, Bialer MG, Lachman RS, Rimoin DL, Cohn DH. Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis. Nat Genet. 2004 Apr; 36(4):405-10. PMID: 14991055.
      View in: PubMed
    114. Miller GD, Rejeski WJ, Williamson JD, Morgan T, Sevick MA, Loeser RF, Ettinger WH, Messier SP. The Arthritis, Diet and Activity Promotion Trial (ADAPT): design, rationale, and baseline results. Control Clin Trials. 2003 Aug; 24(4):462-80. PMID: 12865040.
      View in: PubMed
    115. Jamal MM, Morgan T. Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol. 2003 Aug; 17(4):649-62. PMID: 12828960.
      View in: PubMed
    116. Morgan T, Brenner D, Everhart J, French SW, Fried MW, Gretch DR, Koziel MJ, McClain CJ, Peters MG, Weinman SA, Lucas DL. Hepatitis C and alcohol: fundamental and translational research directions. Alcohol Clin Exp Res. 2003 Apr; 27(4):726-31. PMID: 12711937.
      View in: PubMed
    117. Crouse JR, Tang R, Espeland MA, Terry JG, Morgan T, Mercuri M. Associations of extracranial carotid atherosclerosis progression with coronary status and risk factors in patients with and without coronary artery disease. Circulation. 2002 Oct 15; 106(16):2061-6. PMID: 12379574.
      View in: PubMed
    118. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol. 2002 Sep; 97(9):2391-7. PMID: 12358262.
      View in: PubMed
    119. Morgan K, French SW, Morgan T. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology. 2002 Jul; 36(1):122-34. PMID: 12085356.
      View in: PubMed
    120. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002 Mar; 35(3):688-93. PMID: 11870385.
      View in: PubMed
    Timothy's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _